Stealth BioTherapeutics EBIT

Stealth BioTherapeutics (MITO) currently reports a EBIT of $-48M as of March 2022. That compares with $-52M in the prior-year period — up 6.8% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore Stealth BioTherapeutics's EBIT history and peer comparisons.

Stealth BioTherapeutics's EBIT increased from $-52M to $-48M — a 6.8% year-over-year increase (period ending March 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Stealth BioTherapeutics's EBIT of $-48M is lower than the Healthcare sector average of $23B. That is roughly 100.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Stealth BioTherapeutics reported $-48M in EBIT as of March 2022. That compares with $-52M in the prior-year period — up 6.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-48M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Stealth BioTherapeutics, and consider following MITO for alerts when major investors trade the stock.